Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axogen, Inc. filings document a Nasdaq-listed operating company focused on peripheral nerve repair technologies and related surgical products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor presentations, FDA-related disclosures for Avance® (acellular nerve allograft-arwx), and material agreements tied to common stock financing and shelf registration activity.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and pay-versus-performance disclosures. The filing record also identifies Axogen’s common stock structure and corporate governance framework, while event reports record officer compensation arrangements, regulatory language for Avance, and other formal updates to the company’s public disclosure record.
Axogen, Inc. director Wendell Amy McBride exercised stock options and sold the resulting shares. On May 8, 2026, she exercised options covering 1,647 shares of common stock at $14.85 per share, then completed an open-market sale of 1,647 shares at a weighted average price of $42.60 per share, with individual sale prices ranging from $42.50 to $42.62. After these transactions, she directly held 93,826 shares of Axogen common stock.
Axogen, Inc. director John Johnson exercised stock options and sold the resulting shares. On May 7, 2026, he exercised options covering 11,050 shares of common stock at $7.04 per share, then sold 11,050 shares in open-market transactions at a weighted average price of $43.255 per share. The sale price reflected multiple trades between $43.25 and $43.35 per share. Following these transactions, Johnson reported holding 0 shares of Axogen common stock directly, and the exercised option grant was fully used.
Axogen, Inc. director Kathy Johnson Weiler exercised options to acquire 16,344 shares of common stock at $6.95 per share, then sold the same 16,344 shares in an open‑market transaction at a weighted average price of $44.091 per share on May 7, 2026.
Following these transactions, she reports holding no common shares directly but retains 27,307 employee stock options with a $6.95 exercise price expiring on December 20, 2033. According to the grant terms, these options vest in three equal annual installments beginning on December 20, 2024.
Axogen, Inc. Chief Marketing Officer Jens Kemp reported an open-market sale of 4,000 shares of Axogen common stock. The weighted average sale price was $43.4403 per share, with individual trades executed between $43.44 and $43.45 per share. Following these transactions, Kemp directly owns 72,451 shares of Axogen common stock.
Axogen, Inc. CFO Lindsey Marie Hartley reported an option-related share transaction. On May 7, 2026, she exercised employee stock options to acquire a total of 5,463 shares of common stock at exercise prices of $8.20 and $8.27 per share, and sold 1,051 shares in open-market transactions at $43.67 per share. The options exercised were or will be fully vested under schedules that reach full vesting in March 2026 and March 2027, reflecting routine compensation-related activity.
Axogen, Inc. Sales VP Doris Quackenbush reported an open‑market sale of 3,878 shares of common stock on May 7, 2026. The shares were sold at a weighted average price of $43.507 per share in multiple trades between $43.50 and $44.00. After this transaction, Quackenbush directly holds 92,416 shares of Axogen common stock, as reported in the filing.
Axogen, Inc. Sales VP Doris Quackenbush reported her initial beneficial ownership of company equity. She directly holds 96,294 shares of common stock, along with multiple employee stock options and restricted stock units that may convert into additional common shares as they vest or become exercisable over time.
AXGN filing: Notice of proposed sale under Rule 144. The form lists 3,878 shares of Common stock with a transaction date shown as 05/07/2026 and Nasdaq as the market. The filing identifies two blocks of restricted stock: 541 shares (03/16/2023) and 3,337 shares (02/01/2024), and names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.